Universita degli Studi di Salerno - Centro per le Malattie Neurodegenerative
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Barone, Paolo
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting
N/A
4500
Europe, Canada, US, RoW
Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders
Parkinson Disease
12/33
12/33
Picillo, Marina
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
STIM-PSP, NCT04655079: Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP)

Completed
N/A
24
Europe
Anodal transcranial direct current stimulation (a-tDCS), Active tDCS, Sham Condition
University of Salerno
Progressive Supranuclear Palsy, Motor and Cognitive Symptoms
05/22
05/22
NCT04691635: The MOTIVE-PSP Initiative (Progressive Supranuclear Palsy)

Recruiting
N/A
165
Europe
evaluation of movements with sensors
University of Salerno, Azienda Ospedaliera di Padova, Azienda Ospedaliero, Universitaria Pisana
Progressive Supranuclear Palsy
01/25
01/25

Download Options